What is CGTX stock price today?

CGTX (Cognition Therapeutics Inc) stock is trading at $1.18 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is CGTX stock going up or down today?

CGTX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy CGTX stock now?

The decision to buy CGTX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is CGTX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for CGTX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is CGTX stock overvalued or undervalued?

Use our DCF valuation calculator to determine if CGTX is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is CGTX's P/E ratio?

P/E ratio data for CGTX will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is CGTX's market cap?

CGTX (Cognition Therapeutics Inc) has a market capitalization of $0.11 billion, making it a small-cap stock.

What is CGTX's price to book ratio?

CGTX trades at a price-to-book (P/B) ratio of 3.56, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does CGTX pay dividends?

CGTX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is CGTX's dividend yield?

CGTX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is CGTX stock a good long-term investment?

CGTX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is CGTX's revenue growth rate?

Revenue growth data for CGTX is available on our dashboard with detailed financial statement analysis.

Profitability metrics for CGTX are available on our dashboard with complete income statement analysis.

What are the risks of investing in CGTX?

Key risks for CGTX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does CGTX compare to its competitors?

Compare CGTX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CGTX's performance and positioning.

What is CGTX's stock price target for 2026?

Our AI model provides price targets for CGTX based on fundamental analysis: Bull case $1.53 (+30%), Base case $1.36 (+15%), Bear case $1.06 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about CGTX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for CGTX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is CGTX's next earnings report?

CGTX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

CGTX - Cognition Therapeutics Inc

NYSE * Health Care * Biotechnology

$1.18

$-0.01 (-0.84%)

About Cognition Therapeutics Inc

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.

CGTX Key Statistics

Market Cap

$105.61M

P/B Ratio

3.56

EPS

$-0.23

Employees

How CGTX Compares to Peers

CGTX is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
CGTX(This stock)	$105.61M	N/A	0%	0.0%	-
AMGNAmgen Inc	$181.77B	23.4	0%	0.2%	vs AMGN
GILDGilead Sciences	$166.90B	18.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.59B	26.5	0%	0.4%	vs VRTX
REGNRegeneron Pharmaceuticals	$64.45B	15.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$28.94B	21.1	0%	0.1%	vs BIIB

Cognition Therapeutics Inc Company Information

Headquarters: Pennsylvania; U.S.A
Website: www.cogrx.com
Sector: Health Care
Industry: Biotechnology

Data Updated: June 2, 2026 at 6:41 AM EDT

Ready to invest in CGTX?

Commission-free trading available. Affiliate links.

CGTX Lician Score

5% confidence

4.0/10

Neutral

CGTX has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates CGTXacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

CGTX Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for CGTX

Dashboard

Enter a ticker to analyze